ELX1 007

Drug Profile

ELX1 007

Alternative Names: ELX1-007; ELX1.007; FirstCover

Latest Information Update: 06 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Elanix Biotechnologies
  • Developer Elanix Biotechnologies; University Hospital of Lausanne
  • Class Biological factors; Cytokines; Growth factors; Skin disorder therapies; Tissue extracts
  • Mechanism of Action Tissue replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Wounds

Most Recent Events

  • 06 Sep 2016 Clinical trials in Wounds in Switzerland (Topical)
  • 06 Sep 2016 ELX1 007 receives Advanced Therapeutic Medicinal Product designation in Europe before September 2016 (Elanix Biotechnologies pipeline, September 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top